Black Diamond Therapeutics Inc (NASDAQ:BDTX) — Market Cap & Net Worth
Market Cap & Net Worth: Black Diamond Therapeutics Inc (BDTX)
Black Diamond Therapeutics Inc (NASDAQ:BDTX) has a market capitalization of $95.69 Million ($95.69 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19430 globally and #4400 in its home market, demonstrating a -12.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Black Diamond Therapeutics Inc's stock price $1.67 by its total outstanding shares 57301774 (57.30 Million). Review debt load of Black Diamond Therapeutics Inc to assess the company's total debt and financial obligations.
Black Diamond Therapeutics Inc Market Cap History: 2020 to 2026
Black Diamond Therapeutics Inc's market capitalization history from 2020 to 2026. Data shows change from $1.84 Billion to $95.69 Million (-39.07% CAGR).
Index Memberships
Black Diamond Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #548 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #1885 of 3165 |
Weight: Black Diamond Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Black Diamond Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Black Diamond Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.99x
Black Diamond Therapeutics Inc's market cap is 1.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
6.23x
Black Diamond Therapeutics Inc's market cap is 6.23 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $139.24 Million | $70.00 Million | $22.37 Million | 1.99x | 6.23x |
Competitor Companies of BDTX by Market Capitalization
Companies near Black Diamond Therapeutics Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Black Diamond Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Black Diamond Therapeutics Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Black Diamond Therapeutics Inc's market cap moved from $1.84 Billion to $ 95.69 Million, with a yearly change of -39.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $95.69 Million | -31.28% |
| 2025 | $139.24 Million | +13.55% |
| 2024 | $122.63 Million | -23.84% |
| 2023 | $161.02 Million | +56.11% |
| 2022 | $103.14 Million | -66.23% |
| 2021 | $305.42 Million | -83.37% |
| 2020 | $1.84 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Black Diamond Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $95.69 Million USD |
| MoneyControl | $95.69 Million USD |
| MarketWatch | $95.69 Million USD |
| marketcap.company | $95.69 Million USD |
| Reuters | $95.69 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Black Diamond Therapeutics Inc
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutan… Read more